Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07198087 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants
A Phase 1 study of Primary Central Nervous System Lymphoma (PCNSL), sponsored by Ono Pharmaceutical Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 2
- Study locations
NCT07198087 is a Phase 1 study of Primary Central Nervous System Lymphoma (PCNSL) that is actively recruiting participants, run by Ono Pharmaceutical Co.. The registered enrollment target is 32 participants, below the 177-participant average among 5 other Primary Central Nervous System Lymphoma (PCNSL) trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT07198087, a Phase 1 study of Primary Central Nervous System Lymphoma (PCNSL), is actively recruiting participants, sponsored by Ono Pharmaceutical Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 2
- Study locations
Study Summary
A study to investigate the pharmacokinetics of tirabrutinib in participants with mild, moderate, and severe hepatic impairment compared to healthy participants
Conditions Studied
Interventions
- DRUG Tirabrutinib
Study Locations (2)
Florida
- Panax Clinical Research - Miami Lakes
- Orlando Clinical Research Center, Inc. - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07198087
The ClinicalTrials.gov registry entry for NCT07198087 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 177-participant average among 5 other Primary Central Nervous System Lymphoma (PCNSL) trials with a reported enrollment target (82% lower). The listed sponsor is Ono Pharmaceutical Co., which has 17 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Central Nervous System Lymphoma (PCNSL) appearing as the primary indexed condition, and to 1 intervention - of which Tirabrutinib is the first listed.
NCT07198087 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07198087 about?
NCT07198087 is a clinical study titled "A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants". A study to investigate the pharmacokinetics of tirabrutinib in participants with mild, moderate, and severe hepatic impairment compared to healthy participants
What is the current status of trial NCT07198087?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2025-10-01. Estimated completion is 2026-12-31.
What conditions does trial NCT07198087 study?
This clinical trial studies the following conditions: Primary Central Nervous System Lymphoma (PCNSL).
What interventions are being tested in trial NCT07198087?
The interventions under investigation include: Tirabrutinib (DRUG).
Who is sponsoring clinical trial NCT07198087?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07198087 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Central Nervous System Lymphoma (PCNSL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)
RECRUITING · Phase 1
-
Ibrutinib With Rituximab and Lenalidomide for Patients With Recurrent/Refractory Primary or Secondary Central Nervous System Lymphoma (PCNSL/SCNSL)
COMPLETED · Phase 1
-
Nivolumab Maintenance in Newly Diagnosed PCNSL With Persistent CSF Circulating Tumor DNA After Completion of First-Line Chemotherapy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.